Back to Browse Journals » Biologics: Targets and Therapy » Volume 2 » Issue 4

Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease

Authors Fernando C Fervenza, Roser Torra, David G Warnock

Published 5 December 2008 Volume 2008:2(4) Pages 823—843

DOI https://doi.org/10.2147/BTT.S3770

Review by Single-blind

Peer reviewer comments 6

Fernando C Fervenza1, Roser Torra2, David G Warnock3

1Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, MN, USA; 2Department of Nephrology, Fundació Puigvert, Barcelona, Spain; 3Division of Nephrology, University of Alabama at Birmingham, Birmingham, AL, USA

Abstract: Kidney involvement with progressive loss of kidney function (Fabry nephropathy) is an important complication of Fabry disease, an X-linked lysosomal storage disorder arising from deficiency of α-galactosidase activity. Clinical trials have shown that enzyme replacement therapy (ERT) with recombinant human α-galactosidase clears globotriaosylceramide from kidney cells, and can stabilize kidney function in patients with mild to moderate Fabry nephropathy. Recent trials show that patients with more advanced Fabry nephropathy and overt proteinuria do not respond as well to ERT alone, but can benefit from anti-proteinuric therapy given in conjunction with ERT. This review focuses on the use of enzyme replacement therapy with agalsidase-alfa and agalsidase-beta in adults with Fabry nephropathy. The current results are reviewed and evaluated. The issues of dosing of enzyme replacement therapy, the use of adjunctive agents to control urinary protein excretion, and the individual factors that affect disease severity are reviewed.

Keywords: agalsidase, enzyme replacement therapy, Fabry nephropathy, anti-proteinuric therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Disaster risk profile and existing legal framework of Nepal: floods and landslides

Gaire S, Castro Delgado R, Arcos González P

Risk Management and Healthcare Policy 2015, 8:139-149

Published Date: 3 September 2015

Role of diclofenac in the prevention of postpericardiotomy syndrome after cardiac surgery

Sevuk U, Baysal E, Altindag R, Yaylak B, Adiyaman MS, Ay N, Alp V, Beyazit U

Vascular Health and Risk Management 2015, 11:373-378

Published Date: 30 June 2015

Superparamagnetic iron oxide nanoparticles conjugated with epidermal growth factor (SPION–EGF) for targeting brain tumors

Shevtsov MA, Nikolaev BP, Yakovleva LY, Marchenko YY, Dobrodumov AV, Mikhrina AL, Martynova MG, Bystrova OA, Yakovenko IV, Ischenko AM

International Journal of Nanomedicine 2014, 9:273-287

Published Date: 3 January 2014

Characterization, activity, and computer modeling of a molecular inclusion complex containing rifaldazine

Tan Q, He D, Wu M, Yang L, Ren Y, Liu J, Zhang J

International Journal of Nanomedicine 2013, 8:477-484

Published Date: 1 February 2013

Causal diagrams and the logic of matched case-control studies

Shahar E, Shahar DJ

Clinical Epidemiology 2012, 4:137-144

Published Date: 15 May 2012

Randomized study to compare valsartan ± HCTZ versus amlodipine ± HCTZ strategies to maximize blood pressure control

Dion Zappe, Cheraz Cherif Papst, Philippe Ferber, et al.

Vascular Health and Risk Management 2009, 5:883-892

Published Date: 22 October 2009

Lipid nanoparticles with accessible nickel as a vaccine delivery system for single and multiple his-tagged HIV antigens

Weili Yan, Anekant Jain, Ronan O’Carra,  Jerold G Woodward, et al.

HIV/AIDS - Research and Palliative Care 2009, 1:1-11

Published Date: 17 July 2009

Targeting autophagy: a novel anticancer strategy with therapeutic implications for imatinib resistance

Jennifer S Carew, Steffan T Nawrocki, Francis J Giles, John L Cleveland

Biologics: Targets and Therapy 2008, 2:201-204

Published Date: 6 June 2008